2023
Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy
KLAIL, Tomáš; Petra ŠEDOVÁ; Jan VINKLÁREK; Ingrid KOVACOVA; Michal BAR et. al.Základní údaje
Originální název
Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy
Autoři
KLAIL, Tomáš; Petra ŠEDOVÁ; Jan VINKLÁREK; Ingrid KOVACOVA; Michal BAR; Filip CIHLAR; David CERNIK; Lubomir KOCI; René JURA; Roman HERZIG; Jakub HUSTÝ; Martin KOCHER; Martin KOVAR; Miroslava NEVSIMALOVA; Jan RAUPACH; Miloslav ROCEK; Daniel SANAK; Petr SEVCIK; David SKOLOUDIK; Martin SRAMEK; Jiří VANÍČEK; Peter VASKO; Daniel VACLAVIK; Ales TOMEK a Robert MIKULÍK
Vydání
Journal of vascular and interventional radiology, New York, ELSEVIER, 2023, 1051-0443
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30210 Clinical neurology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.600
Kód RIV
RIV/00216224:14110/23:00131949
Organizační jednotka
Lékařská fakulta
UT WoS
001068364800001
EID Scopus
2-s2.0-85162254024
Klíčová slova česky
THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES
Klíčová slova anglicky
THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 5. 4. 2024 08:50, Mgr. Tereza Miškechová
Anotace
V originále
Purpose: To investigate the safety and efficacy of baseline antiplatelet treatment in patients with acute ischemic stroke (AIS) undergoing mechanical thrombectomy (MT). Materials and Methods: Baseline use of antiplatelet medication before MT for (AIS) may provide benefit on reperfusion and clinical outcome but could also carry an increased risk of intracranial hemorrhage (ICH). All consecutive patients with AIS and treated with MT with and without intravenous thrombolysis (IVT) between January 2012 and December 2019 in all centers performing MT nationwide were reviewed. Data were prospectively collected in national registries (eg, SITS-TBY and RES-Q). Primary outcome was functional independence (modified Rankin Scale 0-2) at 3 months; secondary outcome was ICH. Results: Of the 4,351 patients who underwent MT, 1,750 (40%) and 666 (15%) were excluded owing to missing data from the functional independence and ICH outcome cohorts, respectively. In the functional independence cohort (n = 2,601), 771 (30%) patients received antiplatelets before MT. Favorable outcome did not differ in any antiplatelet, aspirin, and clopidogrel groups when compared with that in the no-antiplatelet group: odds ratio (OR), 1.00 (95% CI, 0.84-1.20); OR, 1.05 (95% CI, 0.86-1.27); and OR, 0.88 (95% CI, 0.55-1.41), respectively. In the ICH cohort (n = 3,685), 1095 (30%) patients received antiplatelets before MT. The rates of ICH did not increase in any treatment options (any antiplatelet, aspirin, clopidogrel, and dual antiplatelet groups) when compared with those in the no-antiplatelet group: OR, 1.03 (95% CI, 0.87-1.21); OR, 0.99 (95% CI, 0.83-1.18); OR, 1.10 (95% CI, 0.82-1.47); and OR, 1.43 (95% CI, 0.87-2.33), respectively. Conclusions: Antiplatelet monotherapy before MT did not improve functional independence or increase the risk of ICH.
Návaznosti
| 90249, velká výzkumná infrastruktura |
|